A Phase 1 Clinical Trial Evaluating the Safety and Efficacy of up to Two Administrations of the Adrenal PET Tracer [18F]CETO in Healthy Volunteers and Patients With Primary Aldosteronism
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- University of Cambridge
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Safety of [18F]CETO administration
Study Overview
Brief Summary
The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, [18F]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).
Detailed Description
At least one-quarter of the UK adult population has hypertension, a major risk factor for heart attacks and stroke. Primary aldosteronism (PA), a treatable form of hypertension, accounts for 5-10% of all cases, and 20-25% of difficult to control hypertension. It is challenging to determine whether one adrenal gland is the source of PA (which is potentially curable with surgery) or both glands (which would require long-term drug treatment). Existing lateralising procedures (i.e. investigations to distinguish one from two gland involvement e.g. CT or MRI scan) have significant limitations. Accordingly, most patients must undergo an invasive procedure called adrenal vein sampling (AVS) in which small catheters are placed in each adrenal vein. However, this is time-consuming, technically demanding, and fails in 20-50% of cases. To address this, researchers have adopted a novel approach using PET-CT as an alternative to AVS. Currently, this uses a tracer called metomidate labelled with carbon-11 (11C MTO), which is taken up preferentially by the adrenal gland, and in particular by adrenal tumours causing PA. However, its utility is limited by a short half-life, which means the scan can only be performed in centres with a cyclotron facility (currently less than 10 NHS sites). The aim of this study is to investigate the safety of a new tracer with a longer half-life, [18F]CETO, that could be made available for use in many more centres.
The trial objectives are outlined below:
Primary Objective
To evaluate the safety of up to two administrations of [18F]CETO in up to 6 patients with primary aldosteronism and 5 healthy volunteers.
Secondary Objective
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- Single (Outcomes Assessor)
Masking Description
Scans will be assessed by two independent nuclear medicine physicians, who will be blinded to patient identifiable data when analysing PET-CT scans.
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy Volunteers
- •To be included in the trial the participant must:
- •give written informed consent
- •be aged 50 years or over
- •have no underlying medical conditions
- •be able to lie down for at least 2 hours and not be claustrophobic
- •In addition, all female participants must be:
- •post-menopausal (no menses for 12 months, without an alternative medical cause)
- •To be included in the trial the patient must:
- •give written informed consent
- •be aged 40 years or over
- •be able to lie down for at least 2 hours and not be claustrophobic
- •fulfil the following criteria:
- •have a confirmed diagnosis of PA as per Endocrine Society guidelines
- •At least one paired measurement of plasma renin and aldosterone, measured off Spironolactone/Eplerenone within past 12 months, showing ARR above local threshold value.
- •One of the following two criteria:
- •Plasma aldosterone>190pmol/L following saline infusion.
- •Spontaneous hypokalaemia, suppressed plasma renin and plasma aldosterone>550pmol/L.
- •have undergone successful lateralisation of the cause of PA to one or both adrenal glands by adrenal vein sampling (AVS).
- •be willing to have two scans
- •In addition, all female patients must have a negative (blood) pregnancy test at the screening visit.
Exclusion Criteria
- •All participants:
- •allergy to radiographic contrast agents
- •allergy or contraindication to synacthen
- •pregnancy, breastfeeding, or the intention to become pregnant during the 6 months following trial participation
- •positive pregnancy test at the screening or baseline visits
- •assessed by the investigator as being unable or unwilling to comply with the requirements of the study protocol.
- •receipt of another IMP as part of a CTIMP
- •prior radiation exposure as part of previous research studies
- •recreational drug use, or substance/alcohol dependency
- •clinically abnormal screening blood tests.
- •Additional exclusion criteria for healthy volunteers:
- •women of child-bearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile)
- •exposure to radiation during their work
- •received more than 10 mSv of radioactivity in the past 12 months
- •any subject with a history of adrenal disease or who, at the screening visit, reports symptoms, or exhibits physical signs, that could be consistent with previously unsuspected adrenal disease
- •Additional exclusion criteria for patients:
- •allergy or contraindication to dexamethasone treatment (or lactose intolerant)
Arms & Interventions
Patients with primary aldosteronism
A group of 6 patients with Primary Aldosteronism (3 with unilateral and 3 with bilateral disease) will be tested with up to two administrations of the PET radiotracer [18F]CETO, to assess safety of tracer administration, evaluate the ability of [18F]CETO to distinguish between unilateral and bilateral cases of PA, and determine the effect of Dexamethasone in improving the quality of PET-CT images acquired following administration.
Intervention: [18F]CETO (Combination Product)
Healthy Volunteers
A group of 5 healthy volunteers will be tested with the PET radiotracer [18F]CETO to assess safety of tracer administration, and evaluate uptake by the normal adrenal glands.
Intervention: [18F]CETO (Combination Product)
Outcomes
Primary Outcomes
Safety of [18F]CETO administration
Time Frame: 6 months
The primary outcome measure is the overall safety of \[18F\]CETO. This will be assessed according to the frequency of adverse events, serious adverse events, clinically significant changes in vital signs, ECG and laboratory parameters.
Secondary Outcomes
- [18F]CETO uptake by the the adrenal glands.(6 months)
- To evaluate uptake in bilateral versus unilateral cases of PA following [18F]CETO administration in up to 6 patients.(6 months)
Investigators
Professor Mark Gurnell
Professor in Clinical Endocrinology and Honorary Consultant
University of Cambridge